ReadYourDNA

Acenocoumarol

Raw research findings for this medication. Mostly single studies, not curated or confirmed robust.

About Acenocoumarol

What it is

Acenocoumarol is a coumarin anticoagulant, a close relative of warfarin: it blocks vitamin K from doing its part in making clotting factors, so blood takes longer to clot. It is used, mainly in parts of Europe and Latin America, to prevent and treat blood clots and to lower the chance of stroke in atrial fibrillation. It is sold as Sintrom, among other names.

How genes come into it

The same genes that shape warfarin treatment shape acenocoumarol. VKORC1 makes the enzyme it blocks, and the common variant rs9923231 makes less of it, so less acenocoumarol has the same effect. CYP2C9 breaks it down, and its *2 and *3 versions slow that; CYP4F2 plays a smaller part. DPWG has published a guideline on VKORC1 and acenocoumarol, and well over a hundred studies have looked at these and other genes.

Published guidelines

Clinical guidelines that name a gene for Acenocoumarol. They sort people into groups by the gene copies they carry.

DPWG guideline: VKORC1. rs9923231 C/C · rs9923231 T/T · rs9923231 C/T. 2011.

What research found

Every published finding on gene variants and Acenocoumarol. Upload your DNA file to see which of these rows apply to you.

Rated evidence (17 rated variants)

PharmGKB weighs all studies of a variant and rates how strong the evidence is, from 1A (strongest) to 4.

VKORC1 rs9923231: Level 1A · replicated. Dosage. 20.

CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3: Level 1B · replicated. Dosage. 35.

CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3: Level 1B · replicated. Toxicity: over-anticoagulation. 15.

CYP4F2 rs2108622: Level 2A · replicated. Dosage: Atrial Fibrillation. 14.

Metabolism (3 findings)

Studies of how quickly the body processes this medication.

CYP2C9 CYP2C9*1, CYP2C9*2, CYP2C9*3: CYP2C9 *1/*3 + *2/*3 are associated with decreased clearance of acenocoumarol as compared to CYP2C9 *1/*1.

CYP2C9 CYP2C9*1, CYP2C9*3: CYP2C9 *1/*3 is associated with decreased clearance of acenocoumarol as compared to CYP2C9 *1/*1.

CYP2C9 CYP2C9*1, CYP2C9*5, CYP2C9*8, CYP2C9*9, CYP2C9*11: CYP2C9 *9/*11 + *5/*8 are associated with decreased metabolism of acenocoumarol in healthy individuals as compared to CYP2C9 *1/*1.

Response (11 findings)

Studies of how well it worked in people carrying a variant.

CYP2C9 CYP2C9*2: CYP2C9 *2 is associated with increased response to acenocoumarol as compared to CYP2C9 *1.

CYP2C9 CYP2C9*3: CYP2C9 *3 is associated with increased response to acenocoumarol as compared to CYP2C9 *1.

CYP2C9 CYP2C9*3: CYP2C9 *3 is associated with increased response to acenocoumarol in healthy individuals as compared to CYP2C9 *1.

VKORC1 rs9923231: Allele T is associated with increased response to acenocoumarol in healthy individuals as compared to allele C.

Dosing (135 findings)

Studies of how much of the drug people needed or tolerated.

APOE rs429358: Genotype CC is associated with increased dose of acenocoumarol in people with Atrial Fibrillation or venous thromboembolism as compared to genotypes CT + TT.

APOE rs429358: Allele C is associated with decreased dose of acenocoumarol in people with venous thromboembolism as compared to allele T.

CALU rs1043550: Allele G is associated with increased dose of acenocoumarol in people with Atrial Fibrillation as compared to allele A.

CYP2C18 rs1998591: Genotype GG is associated with increased dose of acenocoumarol in children as compared to genotypes AA + AG.

Other findings (1 finding)

Studies that do not fall into the groups above.

CYP2C9 rs1057910: Genotype AC is associated with response to acenocoumarol in healthy individuals as compared to genotype AA.

Study findings and evidence levels: PharmGKB (CC BY-SA 4.0). Guidelines: CPIC and DPWG, as bundled in PharmCAT. Most studies were done mainly in people of European ancestry.

Related Drugs

More drugs from the same category

Coumadin (Anticoagulants)

Fluindione (Anticoagulants)

Marcoumar (Anticoagulants)

Not a prescribing recommendation. This page is educational information about pharmacogenomic research and clinical guidelines - it is not medical or dosing advice, and not a prediction of how any medication will work for you. Never start, stop, or change a medication or dose based on it; talk to your doctor or pharmacist, who can order clinical-grade testing if appropriate.

Back to Medications

Content updated September 2026.

ReadYourDNA provides educational interpretation of DNA data you already have. It is not diagnostic, not a substitute for professional medical advice, diagnosis, or treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Talk to a clinician before acting on any result.

Raw DNA Data Reports for 23andMe & AncestryDNA · About ReadYourDNA · FAQ · Methodology & Science · Pricing · Support and complaints · Legal & Contact · Health Traits · Pharmacogenomics · Carrier Status · Variant Explorer · The Human Karyotype · Privacy Policy · Terms of Service · Accessibility · Consumer Health Data Privacy · Your Privacy Choices · Editorial Standards · Your Data, Checkable · Sample Report · ReadYourDNA and Promethease compared · What is inside a 23andMe raw data file · What is inside an AncestryDNA raw data file · What a chatbot can and cannot do with your raw DNA file · Where a raw DNA file can still be uploaded in 2026

Written, maintained and operated by Martin Pechhacker, sole proprietor, Vienna, Austria. Trade register GISA 40064420. support@readyourdna.com